1932

Abstract

This review discusses a growing body of scholarship at the intersection of anthropology and science and technology studies (STS) that examines how drugs are rendered efficacious in laboratories, therapeutic settings, and everyday lives. This literature foregrounds insights into how commercial interests and societal concerns shape the kinds of pharmaceutical effects that are actualized and how some efficacies are blocked in response to moral concerns. The work brought together here reveals how regulatory institutions and health policy makers seek to stabilize pharmaceutical actions while, on the front lines of care, pharmacists, health workers, and users tinker with dosages and indications to tailor pharmaceutical actions to specific circumstances. We show that there is no pure (pharmaceutical) object that precedes its socialization. Pharmaceuticals are not “discovered”; they are made and remade in relation to shifting contexts. This review outlines five key areas of ethnographic and STS research that examines such fluid drugs.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-anthro-102116-041539
2017-10-23
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/anthro/46/1/annurev-anthro-102116-041539.html?itemId=/content/journals/10.1146/annurev-anthro-102116-041539&mimeType=html&fmt=ahah

Literature Cited

  1. ’t Hoen E. 2002. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. Chicago J. Int. Law 3:127–46 [Google Scholar]
  2. Adams V. 2016. Metrics: What Counts in Global Health Durham, NC: Duke Univ. Press
  3. Akrich M. 1992. The de-scription of technical objects. Shaping Technology/Building Society. Studies in Sociotechnical Change J Bijker, W Law 205–24 Cambridge, MA: MIT Press [Google Scholar]
  4. Akrich M. 1995. Petite anthropologie du médicament. Tech. Cult.25–26
  5. Applbaum K. 2009. Getting to yes: corporate power and the creation of a psychopharmaceutical blockbuster. Cult. Med. Psychiatry 33:2185–215 [Google Scholar]
  6. Applbaum K, Oldani M. 2010. Introduction: Towards an era of bureaucratically controlled medical compliance?. Special Issue: Towards Era Bureaucratically Control. Med. Compliance? K Applbaum, M Oldani Anthropol. Med 17:2113–27 [Google Scholar]
  7. Baglia J. 2005. The Viagra Ad Venture: Masculinity, Marketing, and the Performance of Sexual Health New York: Peter Lang
  8. Banerjee D. 2016. Markets and molecules: a pharmaceutical primer from the south. Med. Anthropol 13:1–18 [Google Scholar]
  9. Barry A. 2005. Pharmaceutical matters: the invention of informed materials. Theory Cult. Soc. 22:151–69 [Google Scholar]
  10. Bensaude-Vincent B, Stengers I. 1996. A History of Chemistry Cambridge, MA: Harvard Univ. Press
  11. Berg M, Mol A. 1998. Differences in Medicine: Unraveling Practices, Techniques, and Bodies Durham, NC: Duke Univ. Press
  12. Biehl J. 2007. Pharmaceuticalization: AIDS treatment and global health politics. Anthropol. Q. 80:41083–126 [Google Scholar]
  13. Biehl J, Petryna A. 2013. When People Come First: Critical Studies in Global Health Princeton, NJ: Princeton Univ. Press
  14. Blaikie C. 2015. Wish-fulfilling jewel pills: Tibetan medicines from exclusivity to ubiquity. Anthropol. Med. 22:17–22 [Google Scholar]
  15. Brives C, Le Marcis F, Sanabria E. 2016. What's in a context? Tenses and tensions in evidence-based medicine. Med. Anthropol 35:5369–76 [Google Scholar]
  16. Cassier M, Corrêa M. 2009. Éloge de la copie: le reverseengineering des antirétroviraux contre le VIH/sida dans les laboratoires pharmaceutiques Brésiliens. Sci. Soc. Santé 27:377–103 [Google Scholar]
  17. Cassier M, Correa M. 2014. Access to medicines in developing countries: ethical demands and moral economy. Dev. World Bioeth. 14:2ii–viii [Google Scholar]
  18. Chaput de Saintonge D, Herxheimer A. 1994. Harnessing placebo effects in health care. Lancet 344:995–98 [Google Scholar]
  19. Conrad P. 2006. Identifying Hyperactive Children: The Medicalization of Deviant Behavior Abingdon, UK: Routledge. Expand
  20. Cousins T. 2015a. A mediating capacity: toward an anthropology of the gut. Med. Anthropol. Theory 2:21–27 [Google Scholar]
  21. Cousins T. 2015b. HIV and the remaking of hunger and nutrition in South Africa: biopolitical specification after apartheid. BioSocieties 10:2143–61 [Google Scholar]
  22. Cousins T. 2016. Antiretroviral therapy and nutrition in Southern Africa: citizenship and the grammar of hunger. Med. Anthropol 35:5433–46 [Google Scholar]
  23. Craig SR. 2012. Healing Elements: Efficacy and the Social Ecologies of Tibetan Medicine Berkeley/London: Univ. Calif. Press
  24. Crowley-Matoka M, True G. 2012. No one wants to be the candy man: ambivalent medicalization and clinician subjectivity in pain management. Cult. Anthropol. 27:4689–712 [Google Scholar]
  25. Das V, Das RK. 2006. Pharmaceuticals in urban ecologies: the register of the local. See Petryna et al. 2006 171–205
  26. Davis C, Abraham J. 2013. Unhealthy Pharmaceutical Regulation: Innovation, Politics and Promissory Science New York: Palgrave Macmillan
  27. De Zordo S. 2016. The biomedicalisation of illegal abortion: the double life of misoprostol in Brazil. Hist. Cienc. Saude Manguinhos 23:219–35 [Google Scholar]
  28. Degrandpre R. 2006. The Cult of Pharmacology: How America Became the World's Most Troubled Drug Culture Durham, NC: Duke Univ. Press
  29. DeSantis A, Webb EM, Noar SM. 2008. Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. J. Am. Coll. Health 57:3315–24 [Google Scholar]
  30. Doshi P, Dickersin K, Healy D, Swaroop Vedula S, Jefferson T. 2013. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 346:f2865 [Google Scholar]
  31. Droney D. 2016. Networking health: multi-level marketing of health products in Ghana. Anthropol. Med. 23:11–13 [Google Scholar]
  32. Dumit J. 2012. Drugs for Life: How Pharmaceutical Companies Define Our Health Durham, NC: Duke Univ. Press
  33. Dyke E. 2008. Psychedelic Psychiatry: LSD from Clinic to Campus Baltimore, MD: Johns Hopkins Univ. Press
  34. Ecks S. 2013. Eating Drugs: Psychopharmaceutical Pluralism in India New York: NYU Press
  35. Ecks S, Basu S. 2009. The unlicensed lives of antidepressants in India: generic drugs, unqualified practitioners, and floating prescriptions. Transcult. Psychiatry 46:186–106 [Google Scholar]
  36. Edmonds A, Sanabria E. 2014. Medical borderlands: engineering the body with plastic surgery and hormonal therapies in Brazil. Anthropol. Med. 21:2202–16 [Google Scholar]
  37. Epstein S. 1998. Impure Science: AIDS, Activism, and the Politics of Knowledge Berkeley: Univ. Calif. Press
  38. Epstein S. 2004. Bodily differences and collective identities: the politics of gender and race in biomedical research in the United States. Body Soc 10:2183–203 [Google Scholar]
  39. Etkin NL. 1992. “Side effects”: cultural constructions and reinterpretations of western pharmaceuticals. Med. Anthropol. Q 6:99–113 [Google Scholar]
  40. Fortun K. 2012. Ethnography in late industrialism. Cult. Anthropol. 27:3446–64 [Google Scholar]
  41. Fortun K, Fortun M, Bigras E, Saheb T, Costelloe-Kuehn B. et al. 2014. Experimental ethnography online: the asthma files. Cult. Stud. 28:632–42 [Google Scholar]
  42. Fraser M. 2003. Material theory: duration and the serotonin hypothesis of depression. Theory Cult. Soc. 20:51–26 [Google Scholar]
  43. Garriott W, Raikhel E. 2015. Addiction in the making. Annu. Rev. Anthropol. 44:2477–91 [Google Scholar]
  44. Gaudillière J. 2008. Professional or industrial order? Patents, biological drugs, and pharmaceutical capitalism in early twentieth century Germany. Hist. Technol. 24:2107–33 [Google Scholar]
  45. Gaudillière J-P. 2007. L'industrialisation du médicament: une histoire de pratiques entre sciences, techniques, droit et médecine. Gesnerus 64:93–108 [Google Scholar]
  46. Gaudillière J-P, Hess V. 2013. Ways of Regulating Drugs in the 19th and 20th Centuries Basingstoke, UK: Palgrave Macmillan
  47. Gezon L. 2012. Drug Effects: Khat in Biocultural and Socioeconomic Perspective Walnut Creek, CA: Left Coast Press
  48. Gomart E. 2002. Methadone: six effects in search of a substance. Soc. Stud. Sci. 32:293–135 [Google Scholar]
  49. Gomart E, Hennion A. 1999. A sociology of attachment: music amateurs, drug users. Sociol. Rev. 47:S1220–47 [Google Scholar]
  50. Granado S, Manderson L, Obrist B, Tanner M. 2011. Appropriating “malaria”: local responses to malaria treatment and prevention in Abidjan, Côte d'Ivoire. Med. Anthropol 302102–21 [Google Scholar]
  51. Greene J. 2014. Generic: The Unbranding of Modern Medicine Baltimore, MD: Johns Hopkins Univ. Press
  52. Greenslit N. 2005. Depression and consumption: psychopharmaceuticals, branding, and new identity practices. Cult. Med. Psychiatry 29:2477–502 [Google Scholar]
  53. Hardon A. 2006. Contesting contraceptive innovation—reinventing the script. Soc. Sci. Med. 62:2614–27 [Google Scholar]
  54. Hardon A, Idrus NI. 2014. On Coba and Cocok: youth-led drug-experimentation in Eastern Indonesia. Anthropol. Med. 21:2217–29 [Google Scholar]
  55. Hardon A, Idrus NI. 2015. Magic power: changing gender dynamics and sex-enhancement practices among youths in Makassar, Indonesia. Anthropol. Med. 22:249–63 [Google Scholar]
  56. Hardon A, Pool R. 2016. Anthropologists in global health experiments. Med. Anthropol 35:2447–51 [Google Scholar]
  57. Hartley H. 2006. The “pinking” of Viagra culture: drug industry efforts to create and repackage sex drugs for women. Sexualities 9:2363–78 [Google Scholar]
  58. Hayden C. 2007. A generic solution? Pharmaceuticals and the politics of the similar in Mexico. Curr. Anthropol. 48:2475–95 [Google Scholar]
  59. Hayden C. 2012. Rethinking reductionism, or, the transformative work of making the same. Anthropol. Forum 22:3271–83 [Google Scholar]
  60. Healy D. 2006. The new medical Oikumene. See Petryna et al. 2006 61–84
  61. Heimer CA. 2012. Inert facts and the illusion of knowledge: strategic uses of ignorance in HIV clinics. Econ. Soc. 41:217–41 [Google Scholar]
  62. Helman C. 1978. “Feed a cold, starve a fever”—folk models of infection in an English suburban community, and their relation to medical treatment. Cult. Med. Psychiatry 2:2107–37 [Google Scholar]
  63. Henare A, Holbraad M, Wastell S. 2007. Thinking Through Things: Theorising Artefacts Ethnographically London: Routledge
  64. Hsu E. 2012. Plants in medical practice and common sense: on the interface of ethnobotany and medical anthropology. Plants, Health and Healing: On the Interface of Ethnobotany and Medical Anthropology1–48 New York/Oxford, UK: Berghahn [Google Scholar]
  65. Hsu E. 2015. From social lives to playing fields: “the Chinese antimalarial” as artemisinin monotherapy, artemisinin combination therapy and qinghao juice. Anthropol. Med. 22:275–86 [Google Scholar]
  66. Hunt LM, Arar NH. 2001. An analytical framework for contrasting patient and provider views of the process of chronic disease management. Med. Anthropol. Q 15:2347–67 [Google Scholar]
  67. Ingold T. 2011. Being Alive: Essays on Movement, Knowledge and Description Abingdon, UK: Routledge
  68. Ingold T. 2012. Toward an ecology of materials. Annu. Rev. Anthropol. 41:427–42 [Google Scholar]
  69. Jenkins JH. 2011. Pharmaceutical Self: The Global Shaping of Experience in an Age of Psychopharmacology Santa Fe, NM: Sch. Adv. Res. Press [Google Scholar]
  70. Kahn J. 2013. Race in a Bottle: The Story of BiDil and Racialized Medicine in a Post-Genomic Age New York: Columbia Univ. Press
  71. Kamat VR, Nichter M. 1998. Pharmacies, self-medication and pharmaceutical marketing in Bombay, India. Soc. Sci. Med. 47:779–94 [Google Scholar]
  72. Kaptchuk T, Miller F. 2015. Placebo effects in medicine. N. Engl. J. Med. 373:28–9 [Google Scholar]
  73. Kirmayer LJ. 2011. Unpacking the placebo response: insights from ethnographic studies of healing. J. Mind-Body Regul. 1:2112–24 [Google Scholar]
  74. Knaapen L. 2014. Evidence-based medicine or cookbook medicine? Addressing concerns over the standardization of care. Sociol. Compass 8:2823–36 [Google Scholar]
  75. Kohn E. 2013. How Forests Think: Toward an Anthropology Beyond the Human Berkeley: Univ. Calif. Press
  76. Kopytoff I. 1986. The cultural biography of things: commoditization as process. The Social Life of Things: Commodities in Cultural Perspective64–94 Cambridge, UK: Cambridge Univ. Press [Google Scholar]
  77. Kyakuwa M, Hardon A. 2012. Concealment tactics among HIV-positive nurses in Uganda. Cult. Health Sex. 14:Suppl. 1S123–33 [Google Scholar]
  78. Lai L, Farquhar J. 2015. Nationality medicines in China: institutional rationality and healing charisma. Comp. Stud. Soc. Hist. 57:2381–406 [Google Scholar]
  79. Lakoff A. 2000. Adaptive will: the evolution of attention deficit disorder. J. Hist. Behav. Sci. 36:2149–69 [Google Scholar]
  80. Landecker H. 2013. The metabolism of philosophy, in three parts. Dialectic and Paradox: Configurations of the Third in Modernity I Cooper, BF Malkmus 193–224 Bern, Switz.: Peter Lang [Google Scholar]
  81. Landecker H. 2015. Antibiotic resistance and the biology of history. Body Soc 22:19–52 [Google Scholar]
  82. Langlitz N. 2012. Neuropsychedelia: The Revival of Hallucinogen Research Since the Decade of the Brain London: Univ. Calif. Press
  83. Langlitz N. 2016. Is there a place for psychedelics in philosophy? Fieldwork in neuro- and perennial philosophy. Common Knowl 22:2373–84 [Google Scholar]
  84. Langwick SA. 2015. Partial publics: the political promise of traditional medicine in Africa. Curr. Anthropol. 56:2493–514 [Google Scholar]
  85. Laplante J. 2015. Healing Roots: Anthropology in Life and Medicine New York/Oxford, UK: Berghahn
  86. Latour B. 1993. We Have Never Been Modern Cambridge, MA: Harvard Univ. Press
  87. Livingstone J. 2012. Improvising Medicine: An African Oncology Ward in an Emerging Cancer Epidemic Durham, NC: Duke Univ. Press
  88. Lock MM, Nguyen V-K. 2010. An Anthropology of Biomedicine Chichester, UK: Wiley-Blackwell
  89. Marcus GE. 1995. Ethnography in/of the world system: the emergence of multi-sited ethnography. Annu. Rev. Anthropol. 24:95–117 [Google Scholar]
  90. Marks HM. 2000. The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900–1990 Cambridge, UK: Cambridge Univ. Press
  91. Martin E. 2006. The pharmaceutical person. BioSocieties 1:2273–87 [Google Scholar]
  92. Mattes D. 2011. “We are just supposed to be quiet”: the production of adherence to antiretroviral treatment in urban Tanzania. Med. Anthropol 30:2158–82 [Google Scholar]
  93. McGoey L. 2012. Strategic unknowns: towards a sociology of ignorance. Econ. Soc. 41:21–16 [Google Scholar]
  94. Miller F, Colloca L, Kaptchuk T. 2009. The placebo effect: illness and interpersonal healing. Perspect. Biol. Med. 52:2518–39 [Google Scholar]
  95. Moerman DE. 2013. Against the “placebo effect”: a personal point of view. Complement. Ther. Med. 21:2125–30 [Google Scholar]
  96. Moerman DE, Jonas WB. 2002. Deconstructing the placebo effect and finding the meaning response. Ann. Intern. Med. 136:2471–76 [Google Scholar]
  97. Mol A. 2002. The Body Multiple: Ontology in Medical Practice Durham, NC/London, UK: Duke Univ. Press
  98. Mol A. 2008. The Logic of Care: Health and the Problem of Patient Choice Abingdon, UK: Routledge
  99. Montoya MJ. 2007. Bioethnic conscription: genes, race, and Mexicana/o ethnicity in diabetes research. Cult. Anthropol. 221:94–128 [Google Scholar]
  100. Murphy M. 2008. Chemical regimes of living. Environ. Hist. 13:4695–703 [Google Scholar]
  101. Murphy M. 2011. Distributed reproduction. Corpus: An Interdisciplinary Reader on Bodies and Knowledge MJ Casper, P Currah 21–38 Basingstoke, UK: Palgrave Macmillan [Google Scholar]
  102. Myers N. 2015. Rendering Life Molecular: Models, Modelers, and Excitable Matter Durham, NC/London, UK: Duke Univ. Press
  103. Nading AM. 2016. Local biologies, leaky things, and the chemical infrastructure of global health. Med. Anthropol 36:141–56 [Google Scholar]
  104. Nakassis CV. 2013. Brands and their surfeits. Cult. Anthropol. 28:2111–26 [Google Scholar]
  105. Nelson NC, Keating P, Cambrosio A, Aguilar-Mahecha A, Basik M. 2014. Testing devices or experimental systems? Cancer clinical trials take the genomic turn. Soc. Sci. Med. 111:74–83 [Google Scholar]
  106. Nichter M, Vuckovic N. 1994. Agenda for an anthropology of pharmaceutical practice. Soc. Sci. Med. 39:111509–25 [Google Scholar]
  107. Oldani MJ. 2004. Thick prescriptions: toward an interpretation of pharmaceutical sales practices. Med. Anthropol. Q 18:2325–56 [Google Scholar]
  108. Oram M. 2014. Efficacy and enlightenment: LSD psychotherapy and the Drug Amendments of 1962. J. Hist. Med. Allied Sci 69:2221–50 [Google Scholar]
  109. Persson A, Newman CE, Mao L, de Wit J. 2016. On the margins of pharmaceutical citizenship: not taking HIV medication in the “Treatment Revolution” era. Med. Anthropol. Q 30:2359–77 [Google Scholar]
  110. Peterson K. 2014. Speculative Markets: Drug Circuits and Derivative Life in Nigeria Durham, NC: Duke Univ. Press
  111. Petryna A, Kleinman A, Lakoff A. 2006. Global Pharmaceuticals: Ethics, Markets, Practices Durham, NC: Duke Univ. Press
  112. Pollock A. 2012. Medicating Race: Heart Disease and Durable Preoccupations with Difference Durham, NC: Duke Univ. Press
  113. Pordié L. 2015. Hangover free! The social and material trajectories of PartySmart. Anthropol. Med. 22:234–48 [Google Scholar]
  114. Pordié L, Hardon A. 2015. Drugs’ stories and itineraries. On the making of Asian industrial medicines. Anthropol. Med. 22:21–6 [Google Scholar]
  115. Povinelli EA. 2016. Geontologies: A Requiem to Late Liberalism Durham, NC: Duke Univ. Press
  116. Prince R, Geissler P. 2001. Knowledge of herbal and pharmaceutical medicines among Luo children in western Kenya. Anthropol. Med. 8:211–35 [Google Scholar]
  117. Quintero G, Nichter M. 2011. Generation RX: anthropological research on pharmaceutical enhancement, lifestyle regulation, self-medication and recreational drug use. A Companion to Medical Anthropology M Singer, PI Erickson 339–57 Oxford, UK: Wiley-Blackwell [Google Scholar]
  118. Race K. 2009. Pleasure Consuming Medicine: The Queer Politics of Drugs Durham, NC: Duke Univ. Press
  119. Saethre EJ, Stadler J. 2010. Gelling medical knowledge: innovative pharmaceuticals, experience, and perceptions of efficacy. Anthropol. Med. 17:299–111 [Google Scholar]
  120. Sanabria E. 2009. Le médicament, un objet évanescent: essai sur la fabrication et la consommation des substances pharmaceutiques. Tech. Cult. 52–53:168–89 [Google Scholar]
  121. Sanabria E. 2014. “The same thing in a different box”: similarity and difference in pharmaceutical sex hormone consumption and marketing. Med. Anthropol. Q 28:2537–55 [Google Scholar]
  122. Sanabria E. 2016. Plastic Bodies: Sex Hormones and Menstrual Suppression in Brazil Durham, NC: Duke Univ. Press
  123. Sismondo S. 2010. Linking research and marketing, a pharmaceutical innovation. Perspectives on Twentieth-Century Pharmaceuticals V Quirke, J Slinn 241–56 Bern, Switz.: Peter Lang [Google Scholar]
  124. Sismondo S. 2015. Pushing knowledge in the drug industry: ghost-managed science. The Pharmaceutical Studies Reader S Sismondo, JA Greene 150–64 Oxford, UK: Oxford Univ. Press [Google Scholar]
  125. Strathern M. 2005. Kinship, Law and the Unexpected: Relatives Are Always a Surprise Cambridge, UK: Cambridge Univ. Press
  126. Strathern M. 2014. Reading relations backwards. J. R. Anthropol. Inst. 20:23–19 [Google Scholar]
  127. Sunder Rajan K. 2017. Pharmocracy: Value, Politics, and Knowledge in Global Biomedicine Durham, NC: Duke Univ. Press
  128. Thompson JJ, Ritenbaugh C, Nichter M. 2009. Reconsidering the placebo response from a broad anthropological perspective. Cult. Med. Psychiatry 33:2112–52 [Google Scholar]
  129. Trnka S. 2014. Domestic experiments: familial regimes of coping with childhood asthma in New Zealand. Med. Anthropol 33:2546–60 [Google Scholar]
  130. van der Geest S, Whyte SR. 1989. The charm of medicines: metaphors and metonyms. Med. Anthropol. Q 3:2345–67 [Google Scholar]
  131. van der Geest S, Whyte SR, Hardon A. 1996. The anthropology of pharmaceuticals: a biographical approach. Annu. Rev. Anthropol. 25:153–78 [Google Scholar]
  132. Wahlberg A. 2014. Herbs, laboratories, and revolution: on the making of a national medicine in Vietnam. East Asian Sci. Technol. Soc. 8:143–56 [Google Scholar]
  133. Walsh V, Goodman J. 2002. From taxol to taxol®: the changing identities and ownership of an anti-cancer drug. Med. Anthropol. Cross-Cult. Stud. Health Illn 21:3–4307–36 [Google Scholar]
  134. Wentzell E. 2011. Marketing silence, public health stigma and the discourse of risky gay Viagra use in the US. Body Soc 17:2105–25 [Google Scholar]
  135. Whitmarsh I. 2008. Biomedical Ambiguity: Race, Asthma, and the Contested Meaning of Genetic Research in the Caribbean Ithaca, NY: Cornell Univ. Press
  136. Whyte SR, van der Geest S, Hardon A. 2002. Social Lives of Medicines Camb. Stud. Med. Anthropol Cambridge, UK: Cambridge Univ. Press
  137. Willems D. 1992. Susan's breathlessness: the construction of professionals and lay persons. The Social Construction of Illness J Lachmund, G Stollberg 105–14 Stuttgart, Ger.: Franz Steiner [Google Scholar]
  138. Wilson E. 2015. Gut Feminism Durham, NC: Duke Univ. Press
  139. Winkelman MJ, Roberts TB. 2007. Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments Westport, CT: Praeger [Google Scholar]
  140. Wolf-Meyer M. 2014. Therapy, remedy, cure: disorder and the spatiotemporality of medicine and everyday life. Med. Anthropol 33:2144–59 [Google Scholar]
  141. Wynn LL, Trussell J. 2006. The social life of emergency contraception in the United States: disciplining pharmaceutical use, disciplining sexuality, and constructing zygotic bodies. Med. Anthropol. Q 20:2297–320 [Google Scholar]
/content/journals/10.1146/annurev-anthro-102116-041539
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error